Slide Presentations: Sunday, October 31, 2010 |

Erlotinib on Airway Remodeling After Repeated Ovalbumin Challenge in Brown Norway Rats FREE TO VIEW

Ching-Chi Lin, MD; Shwu-Fang Liaw, MS; Mei-Wei Lin, BS; Feng-Ting Chang, BS
Author and Funding Information

Mackay Memorial Hospital, Taipei, Taiwan ROC

Chest. 2010;138(4_MeetingAbstracts):708A. doi:10.1378/chest.10162
Text Size: A A A
Published online


PURPOSE: Our purpose was to evaluate the effect of Erlotinib on the airway remodeling and airway inflammation in brown-Norway rats (BNR) induced after repeated ovalbumin challenge in BNR.

METHODS: Eighteen BNR were equally divided into three groups. Each group I and II BNR was sensitized by ovalbumin. Fifteen days later, the animals were challenged by ovalbumin for 6 times with 3 days interval in between. Erlotinib (1.5mg/kg/day) was given orally daily for the group I animals and only vehicle was given orally for the group II and group III animals. Group III breathe aerosolized saline under the same conditions as group II animals. After ovalbumin provocation, the animals were anesthetized. Lung tissues were stained with haematoxylin and eosin, Masson’ s trichrome, smooth muscle actin, and von Willebrand factor for microscopic examination.

RESULTS: Our results showed that group II had more severe lung inflammation than the other 2 groups. The airway inflammation, area of collagen deposition surrounding the airways, the mean thickness of the smooth muscle layer surrounding the airways, the mean number of the blood vessels surrounding the airways were lowest in the control group compared to the other 2 groups and significantly lower in the OA-Erlotinib group compared to the OA-saline group. The mean fold change of the mean area of the airway collagen deposition surrounding the airways relative to the control group was 1.7-fold in the OA- Erlotinib group and 3.2-fold in OA-saline group.

CONCLUSION: Erlotinib is effective in preventing airway remodeling and airway inflammation in BNR after repeated ovalbumin challenge.

CLINICAL IMPLICATIONS: Erlotinib may be effective in preventing airway remodeling and airway inflammation in asthma.

DISCLOSURE: Ching-Chi Lin, No Financial Disclosure Information; No Product/Research Disclosure Information

09:45 AM - 11:00 AM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543